Rondy, MarcGherasim, Alin ManuelCasado, ItziarLaunay, OdileRizzo, CaterinaPitigoi, DanielaMickiene, AukseMarbus, Sierk DMachado, AusendaSyrjänen, Ritva KPem-Novose, IvaHorváth, Judit KrisztinaLarrauri, AmparoCastilla, JesúsVanhems, PhilippeAlfonsi, ValeriaIvanciuc, Alina EKuliešė, Monikavan Gageldonk-Lafeber, RianneGomez, VerónicaIkonen, NiinaLovric, ZvjezdanaFerenczi, AnnamáriaI-MOVE+ hospital working groupMoren, Alain2020-01-302020-01-302017Euro Surveill. 2017 Oct;22(41).1560-7917http://hdl.handle.net/20.500.12105/8994In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.engVoRhttp://creativecommons.org/licenses/by/4.0/A(H3N2)InfluenzaCases controlElderlyHospitalisationVaccine effectivenessAdolescentAdultAgedEuropean UnionFemaleHospitalizationHospitalsHumansInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesInfluenza, HumanMaleMiddle AgedOutcome Assessment, Health CareSeasonsAtribución 4.0 Internacional29043961224110.2807/1560-7917.ES.2017.22.41.17-006451560-7917Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinopen access